European Commission: Timing And Priorities For Regulation Implementation
The European Commissioner recently laid out more specifics on its anticipated timing for the roll-out of key priorities in the implementation of the EU Medical Device and IVD Regulations.
You may also be interested in...
Will it be better to continue compliance under the Medical Devices Directive or switch to compliance under the new Medical Devices Regulation when there is a choice? The pros and cons make it a difficult decision.
Attorneys say Sarepta did not have an obligation to report its appeal, particularly since winning a formal dispute filing with the US FDA is a long shot.
Sarepta’s Vyondys: Renal Toxicity Concerns That Delayed Approval Get Enhanced Postmarketing Scrutiny, Label Warning
Sarepta must perform enhanced pharmacovigilance for serious renal toxicity events and rhabdomyolysis with the Duchenne muscular dystrophy drug, which carries a label warning for renal toxicity. Approval letter includes 2024 target completion date for ESSENCE confirmatory trial.